A recent study reveals that weight loss injections are linked to stopping symptoms of depression and schizophrenia.

A recent study published in The Lancet Psychiatry found that weight-loss medications known as GLP-1, including Ozempic, Wigovi, and Mongaro, may be associated with a lower risk of hospitalization for psychiatric crises in people with schizophrenia.

Researchers led by a team from Deakin University in Australia analyzed the health records of more than 70,000 adults in the United States who suffer from schizophrenia and type 2 diabetes.

The results showed that patients who used GLP-1 medications were 24 percent less likely to be hospitalized for psychological reasons, compared to those who did not use diabetes medications, and their likelihood of resorting to emergency departments due to psychological crises decreased by 29 percent.

Benefits beyond weight loss?

The researchers noted that the association between the use of these medications and a reduced need for emergency psychiatric care was stronger in patients who lost weight. But the results also showed a reduced risk for some patients whose weight did not change or who gained additional weight, suggesting there may be effects beyond the weight loss itself.

Drugs associated with these outcomes included semaglutide, the active ingredient in Ozempic and Wigovi, and tirzepatide, used in Mongaro, as well as liraglutide.

Can it help treat depression?

Previous research suggests that these medications may have positive effects on mental health, including symptoms of depression and anxiety. Researchers from the Swiss University of Bern reviewed 36 studies that included about 26,000 people, and found that the use of these medications was associated with an improvement in psychological and emotional well-being.

Researchers believe that these effects are related to the ability of potential drugs to reduce inflammation in the body and brain, but the exact mechanisms have not yet been resolved. These results are particularly important for people with severe psychological disorders, as some antipsychotic medications may lead to weight gain and insulin resistance, which increases the risk of type 2 diabetes.

Can weight loss injections be used to treat psychological disorders?

Despite the encouraging results, researchers cautioned against considering weight-loss injections as a treatment for depression or schizophrenia at this time.

The study is based on observation and analysis of health records, and does not prove that these medications are the direct cause of the decrease in psychological crises. The researchers stressed the need for additional clinical trials to verify the results, and to see if the potential benefits also include people with schizophrenia who do not suffer from diabetes.

Despite the promising results, researchers stress that these medications are not an approved treatment for psychological disorders, and that more studies and clinical trials are needed to prove their effectiveness. Will weight loss injections become a new tool in the treatment of mental illness in the future?